Page last updated: 2024-12-08
lephetamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
lephetamine: RN given refers to (R)-(-)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 443970 |
| CHEMBL ID | 3185938 |
| CHEBI ID | 134927 |
| SCHEMBL ID | 24298 |
| MeSH ID | M0058531 |
Synonyms (30)
| Synonym |
|---|
| lefetamine |
| dl-n,n-dimethyl-1,2-diphenyl-ethylamine |
| dea no. 1635 |
| CHEBI:134927 |
| lephetamine |
| n,n-dimethyl-1,2-diphenylethanamine |
| (1r)-n,n-dimethyl-1,2-diphenylethanamine |
| tox21_112703 |
| cas-7262-75-1 |
| dtxcid5026833 |
| dtxsid7046833 , |
| unii-4j9726v5y9 |
| ethylamine, n,n-dimethyl-1,2-diphenyl-, (-)- |
| (-)-n,n-dimethyl-1,2-diphenylethylamine |
| lefetaminum [inn-latin] |
| lefetamina |
| lefetamina [inn-spanish] |
| 4j9726v5y9 , |
| lefetamine [inn] |
| 1-dimethylamino-1,2-diphenylethane |
| benzeneethanamine, n,n-dimethyl-alpha-phenyl-, (alphar)- |
| lefetaminum |
| 7262-75-1 |
| benzeneethanamine, n,n-dimethyl-alpha-phenyl-, (r)- |
| lefetamine [who-dd] |
| lefetamine [mi] |
| SCHEMBL24298 |
| CHEMBL3185938 |
| Q1064655 |
| [(1r)-1,2-diphenylethyl]dimethylamine |
Research Excerpts
Overview
Lephetamine (L-SPA) is a compound with central analgesic and anti-inflammatory action. Recently reported to be abused in Italy.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lephetamine is a central analgesic, recently shown to be abused by drug addicts and to induce dependence in humans. " | ( Dual effects of lephetamine on spontaneous and evoked neuronal firing in the somatosensory cortex of the rat. Janiri, L; Persico, AM; Tempesta, E, 1989) | 2.07 |
| "Lephetamine (L-SPA) is a compound with central analgesic and anti-inflammatory action, recently reported to be abused in Italy. " | ( Lephetamine abuse and dependence: clinical effects and withdrawal syndrome. Janiri, L; Lo Monaco, M; Mannelli, P; Pirrongelli, C; Tempesta, E, 1989) | 3.16 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (2)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 33.4915 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 33.4915 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (19)
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 14 (63.64) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.75
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.75) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (20.83%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (4.17%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||